Danish Bawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Danish Bawa has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Dhanunjaya Lakkireddy
Kansas City Heart Rhythm Institute, Overland Park, USA
5 shared publications Adnan Ahmed
Kansas City Heart Rhythm Institute, HCA Midwest Health, Overland Park, Kansas, USA
4 shared publicationsNaga Venkata K. Pothineni
Kansas City Heart Rhythm Institute, HCA Midwest Health, Overland Park, Kansas, USA
3 shared publicationsNicholas Pham
Kansas City Heart Rhythm Institute, HCA Midwest Health, Overland Park, Kansas, USA
3 shared publicationsRajesh Kabra
Kansas City Heart Rhythm Institute, HCA Midwest Health, Overland Park, Kansas, USA
3 shared publicationsDouglas Darden
Kansas City Heart Rhythm Institute, HCA Midwest Health, Overland Park, Kansas, USA
2 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Open AccessModerate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- Open Access
- 28 August 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 102057
Role of Artificial Intelligence in Reducing Data Deluge From Cardiac Implantable Electronic Devices
- 28 August 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 102057
Open AccessRole of Artificial Intelligence in Reducing Data Deluge From Cardiac Implantable Electronic Devices
- 21 August 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (10) , 2029-2038
Outcomes of hybrid surgical ablation and concomitant left atrial appendage exclusion in long‐standing persistent atrial fibrillation
Introduction: Management of patients with long‐standing persistent atrial fibrillation (LSPAF) presents a clinical challenge. Hybrid convergent ablation has been shown to have superior efficacy compared to endocardial‐only ablation. However, data on concomitant left atrial appendage (LAA) management along with hybrid ablation is sparse.Methods: We aimed to evaluate the effectiveness of concomitant hybrid convergent ablation and LAA clipping in patients with LSPAF. We conducted a retrospective analysis of all patients with LSPAF who underwent hybrid surgical ablation with LAA clipping at our institution. The primary endpoint was a recurrence of atrial arrhythmias at 12 months. Further, the durability of surgical left atrial posterior wall ablation was examined during the endocardial catheter ablation using standing electrophysiological criteria.Results: A total of 79 patients were included. Mean age was 63.5 ± 9.6 years, and 71% were males. LAA clipping was performed in 99% of patients. The mean time between the surgical and endocardial stages of the procedure was 2.6 ± 1.7 months. Persistent posterior wall activity was observed in 34.2% (n = 27/79) patients during the endocardial phase of the procedure. Cardiac implantable electronic device was used in 74% of patients for monitoring of recurrence of atrial fibrillation (AF). The primary effectiveness of AF freedom at 12 months was 73.8% (45/61). Over a 12‐month follow‐up period, 11.4% (9/79) of patients required repeat catheter ablation, of which 88.9% (8/9) had evidence of persistent posterior wall activity.Conclusion: Concomitant hybrid convergent ablation and LAA exclusion with an atrial clip provides reasonable long‐term AF‐free survival in patients with LSPAF. Persistent posterior wall activity is seen commonly in patients presenting with recurrent AF following hybrid convergent AF ablation.
- 21 August 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (10) , 2029-2038
Outcomes of hybrid surgical ablation and concomitant left atrial appendage exclusion in long‐standing persistent atrial fibrillation
Introduction: Management of patients with long‐standing persistent atrial fibrillation (LSPAF) presents a clinical challenge. Hybrid convergent ablation has been shown to have superior efficacy compared to endocardial‐only ablation. However, data on concomitant left atrial appendage (LAA) management along with hybrid ablation is sparse.Methods: We aimed to evaluate the effectiveness of concomitant hybrid convergent ablation and LAA clipping in patients with LSPAF. We conducted a retrospective analysis of all patients with LSPAF who underwent hybrid surgical ablation with LAA clipping at our institution. The primary endpoint was a recurrence of atrial arrhythmias at 12 months. Further, the durability of surgical left atrial posterior wall ablation was examined during the endocardial catheter ablation using standing electrophysiological criteria.Results: A total of 79 patients were included. Mean age was 63.5 ± 9.6 years, and 71% were males. LAA clipping was performed in 99% of patients. The mean time between the surgical and endocardial stages of the procedure was 2.6 ± 1.7 months. Persistent posterior wall activity was observed in 34.2% (n = 27/79) patients during the endocardial phase of the procedure. Cardiac implantable electronic device was used in 74% of patients for monitoring of recurrence of atrial fibrillation (AF). The primary effectiveness of AF freedom at 12 months was 73.8% (45/61). Over a 12‐month follow‐up period, 11.4% (9/79) of patients required repeat catheter ablation, of which 88.9% (8/9) had evidence of persistent posterior wall activity.Conclusion: Concomitant hybrid convergent ablation and LAA exclusion with an atrial clip provides reasonable long‐term AF‐free survival in patients with LSPAF. Persistent posterior wall activity is seen commonly in patients presenting with recurrent AF following hybrid convergent AF ablation.
- Open Access
- 21 March 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (5) , 100905
Impact of an Organized Treatment Pathway on Management of Atrial Fibrillation
- 21 March 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (5) , 100905
Open AccessImpact of an Organized Treatment Pathway on Management of Atrial Fibrillation
- 1 December 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (12)
Regional Myocarditis due to Legionella Masquerading as Dual-Chamber Cardiac Arrhythmia
- 1 December 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (12)
Regional Myocarditis due to Legionella Masquerading as Dual-Chamber Cardiac Arrhythmia
- 6 September 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (19) , 2460-2462
Coronary Obstruction Following Epicardial Left Atrial Appendage Closure
- 6 September 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (19) , 2460-2462
Coronary Obstruction Following Epicardial Left Atrial Appendage Closure
- Open Access
- 29 June 2022
- Published by Wiley
Low left atrial voltage predicts lack of improvement in left ventricular systolic function post atrial fibrillation ablation in patients with systolic heart failure.
Catheter Ablation of Atrial Fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF) is associated with decreased all-cause mortality, and improvement in left ventricular ejection fraction (EF). Predictors of EF improvement post-AF ablation is not known. In this study we conducted a retrospective review of patients who underwent catheter ablation for AF within last 6 years. 82 Patients undergoing catheter ablation for paroxysmal or persistent AF with EF <45% were included in the study, 18 patients were lost to follow up and therefore were excluded. The patients were divided into 2 groups based on presence or absence of 5% improvement in LVEF post CA, compared to LVEF obtained prior to CA. Mean improvement in EF after ablation was 17±11.8%. As compared to baseline, EF improved by at least 5% in 80% (n=51) of the patients who underwent ablation. Patients with improved EF had significantly higher average total voltage in the LA compared to patients who had no improvement in EF (1.70±1.16 vs 1.00±0.82, p=0.02*). In the multivariable model, after adjusting for other risk factors, LA average total voltage was significantly higher in the group with improved EF (p=0.04*).
- 29 June 2022
- Published by Wiley
Open AccessLow left atrial voltage predicts lack of improvement in left ventricular systolic function post atrial fibrillation ablation in patients with systolic heart failure.
Catheter Ablation of Atrial Fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF) is associated with decreased all-cause mortality, and improvement in left ventricular ejection fraction (EF). Predictors of EF improvement post-AF ablation is not known. In this study we conducted a retrospective review of patients who underwent catheter ablation for AF within last 6 years. 82 Patients undergoing catheter ablation for paroxysmal or persistent AF with EF <45% were included in the study, 18 patients were lost to follow up and therefore were excluded. The patients were divided into 2 groups based on presence or absence of 5% improvement in LVEF post CA, compared to LVEF obtained prior to CA. Mean improvement in EF after ablation was 17±11.8%. As compared to baseline, EF improved by at least 5% in 80% (n=51) of the patients who underwent ablation. Patients with improved EF had significantly higher average total voltage in the LA compared to patients who had no improvement in EF (1.70±1.16 vs 1.00±0.82, p=0.02*). In the multivariable model, after adjusting for other risk factors, LA average total voltage was significantly higher in the group with improved EF (p=0.04*).